Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition and application thereof

A composition and drug technology, applied in the direction of drug combination, pharmaceutical formula, anhydride/acid/halide active ingredients, etc., can solve the problems of combined use of ADHD in children, no atomoxetine hydrochloride and taurine, etc., to reduce Effects of spontaneous hyperactivity behavior, promotion of SOD activity, and inhibition of MDA level

Active Publication Date: 2014-09-24
CHONGQING TECH & BUSINESS UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, there is currently no research on the combination of atomoxetine hydrochloride and taurine for the treatment of ADHD in children, and the study of the combination of the two has good prospects and application value for ADHD in children

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition and application thereof
  • Medicine composition and application thereof
  • Medicine composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1 The effect of the pharmaceutical composition provided by the present invention on the juvenile stage SHR rat ADHD model

[0045] 1), experimental design

[0046] 54 newborn 21-day-old SHR rats ADHD model and 9 WKY rats were taken. After 3 days of adaptive feeding, 52 SHR rats were randomly divided into 6 groups according to body weight, 8-9 rats / group.

[0047] In the experiment, WKY rats were used as negative control;

[0048] The ADHD model of SHR rats without administration was used as the blank control;

[0049] The rats given only atomoxetine hydrochloride were used as the positive control group;

[0050] Three experimental groups with different dosages were set up: among them, experimental group 1 was given a high dose of the pharmaceutical composition, experimental group 2 was given a middle dose of the pharmaceutical composition, and experimental group 3 was given a low dose of the pharmaceutical composition. Administration dosage is as shown in ...

Embodiment 2

[0087] As shown in Table 5, compared with the blank control group, using atomoxetine hydrochloride alone can significantly (P<0.05) up-regulate the brain DBH, TH and Fos expression, and the pharmaceutical composition provided by the invention can be more significant (P<0.05) 0.01) up-regulate the expression of DBH, TH and Fos in the brain, suggesting that atomoxetine hydrochloride, taurine or taurine combined with atomoxetine have a positive effect on noradrenergic neurons and dopaminergic neurons in ADHD rats Protective effect, and the combination of the two drugs has a more significant effect than the single drug. Example 2 Effect of the pharmaceutical composition provided by the present invention on 6-OHDA neonatal rat ADHD model 1), animal modeling and group administration

[0088] When the newborn rats were 5 days old, they were randomly divided into 7 groups, which were: normal control group, model control group, positive control group, and experimental groups 1-3.

[0...

Embodiment 3

[0119] Embodiment 3 Pharmacokinetics and brain distribution research of the pharmaceutical composition provided by the present invention

[0120] In accordance with the relevant content requirements of the "Measures for the Administration of Drug Registration" and the "Guiding Principles for Non-clinical Pharmacokinetic Research of Chemical Drugs", SD rats were used as the subjects, and the effects of atomoxetine hydrochloride alone and in combination with taurine Preliminary study on pharmacokinetics and brain distribution.

[0121] Ten SD rats were randomly divided into two groups, A and B, and fasted for 12 hours before the experiment. Group A was orally administered atomoxetine hydrochloride at a dose of 5 mg / kg; group B was orally administered atomoxetine hydrochloride and taurine at a single dose of 5 mg / kg and 0.9 g / kg, respectively. During the administration process, ensure that the SD rats take the medicine completely. Collect blank blood before administration, collec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, and in particular relates to a medicine composition and an application thereof. The medicine composition comprises atomoxetine hydrochloride and taurine, wherein the synergy can be generated via the combination of the atomoxetine hydrochloride and the taurine. The experiment finds that compared with the single application of the atomoxetine hydrochloride, according to the medicine composition prepared by the combination of the atomoxetine hydrochloride and the taurine, the SOD (Superoxide Dismutase) activity and the GSH (Glutathione) content of the brain tissue of an ADHD (Attention Deficit Hyperactivity Disorder) model rat at a juvenile stage can be obviously increased while the MDA (Methane Dicarboxylic Aldehyde) content (P is less than 0.01) in the brain tissue of the ADHD model rat is decreased, thereby performing an antioxidation function, improving the expressions of DBH (Dopamine Beta-Hydroxylase) and TH (Tyrosine Hydroxylase) in the brain of the ADHD model rat at the juvenile stage and improving the expression (P is less than 0.01) of Fos protein in the prefrontal cortex of the ADHD model rat. Compared with the single application of the medicine, the medicine composition provided by the invention has obvious effects. Thus, the medicine composition can serve as a candidate medicine for treating pediatric hyperactivity.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a medicine composition and its application. Background technique [0002] ADHD, also known as attention deficit hyperactivity disorder (ADHD) or mild brain dysfunction syndrome, is a common abnormal disease in children, and its main impact is to cause abnormal behavior in children. The main clinical manifestations of ADHD in children are: attention deficit, hyperactivity, perception disorder, emotional disturbance, maladaptation, learning difficulties, etc. The causes of the disease may be as follows: dysplasia of brain nerves, insufficient quantity of brain neurotransmitters, organic damage of brain tissue, genetic factors, and other factors. It occurs mostly in children of school age, and the age group with the highest prevalence is 6-12 years old. [0003] At present, many studies have shown that attention deficit hyperactivity disorder (ADHD) in children is mainly a mild ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/185A61P25/00A61P25/14A61K31/138
Inventor 汪程远郑旭煦殷钟意
Owner CHONGQING TECH & BUSINESS UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com